Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Lisinopril 20mg / Hydrochlorothiazide 12.5mg tablets
0205051K0AAAAAA
|
Lisinopril/hydrochlorothiazide | Lisinopril with diuretic | Cardiovascular System | 13,205 |
|
Lisinopril 10mg / Hydrochlorothiazide 12.5mg tablets
0205051K0AAABAB
|
Lisinopril/hydrochlorothiazide | Lisinopril with diuretic | Cardiovascular System | 7,482 |
|
Zestoretic 20 tablets
0205051K0BBAAAA
|
Zestoretic | Lisinopril with diuretic | Cardiovascular System | 472 |
|
Zestoretic 10 tablets
0205051K0BBABAB
|
Zestoretic | Lisinopril with diuretic | Cardiovascular System | 177 |
|
Lisoretic 10mg/12.5mg tablets
0205051K0BFABAB
|
Lisoretic | Lisinopril with diuretic | Cardiovascular System | 12 |
|
Lisoretic 20mg/12.5mg tablets
0205051K0BFAAAA
|
Lisoretic | Lisinopril with diuretic | Cardiovascular System | 4 |
|
Carace 10 Plus tablets
0205051K0BCABAB
|
Carace Plus | Lisinopril with diuretic | Cardiovascular System | No data available |
|
Carace 20 Plus tablets
0205051K0BCAAAA
|
Carace Plus | Lisinopril with diuretic | Cardiovascular System | No data available |
|
Caralpha 10mg/12.5mg tablets
0205051K0BDAAAB
|
Caralpha | Lisinopril with diuretic | Cardiovascular System | No data available |
|
Caralpha 20mg/12.5mg tablets
0205051K0BDABAA
|
Caralpha | Lisinopril with diuretic | Cardiovascular System | No data available |
|
Lisicostad 10mg/12.5mg tablets
0205051K0BEAAAB
|
Lisicostad | Lisinopril with diuretic | Cardiovascular System | No data available |
|
Lisicostad 20mg/12.5mg tablets
0205051K0BEABAA
|
Lisicostad | Lisinopril with diuretic | Cardiovascular System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.